TABLE 1.
Clinical parameters and levels of nasal excretion of PRV following vaccination and PRV challengea
| DNA vaccine or control for each group | Day postvaccination | No. of survivors/total no. in group | Mean relative daily wt (kg/100 kg/ day ± SD)b | Mean body temp at day 2 (°C ± SD) | Nervous symptoms at day 5 (mean score ± SD) | Nasal excretion of PRV (log10 TCID50/g nasal fluid ± SD)
|
|
|---|---|---|---|---|---|---|---|
| Day 2 | Day 5 | ||||||
| PRV-pcDNA3 | 21 | 4/6 | −3.2 ± 0.6 | 40.0 ± 0.5** | 1.7 ± 0.5 | 4.4 ± 0.5* | 5.8 ± 0.3* |
| PRV-pcDNA3 | 5 | 2/5 | −3.6 ± 0.7 | 40.5 ± 0.7 | 0.8 ± 1.0 | 5.9 ± 0.4 | 7.3 ± 0.5 |
| Empty pcDNA3 | 21 | 0/6 | −3.7 ± 0.5 | 41.0 ± 0.2** | 1.0 ± 1.2 | 6.5 ± 0.5 | 7.4 ± 0.3 |
| Empty pcDNA3 | 5 | 0/6 | −3.6 ± 0.7 | 40.9 ± 0.3 | 1.3 ± 1.0 | 6.0 ± 0.3 | 7.4 ± 0.3 |
| No injection, no PRV challenge | 5/5 | NA | 39.3 ± 0.3 | 0.0 | 0.0 | 0.0 | |
a
SD, standard deviation; NA, not applicable; *, P < 0.05; **, P < 0.01, calculated with the nonparametric Mann-Whitney test.
b
For dead pigs, between day of challenge and day of death.